1-甲酰基-3-哌啶甲酰胺 | 130250-55-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-甲酰基-3-哌啶甲酰胺
• 英文名称: N-formylpiperidine-3-carboxamide
• 英文别名: 1-Formylpiperidine-3-carboxamide
• CAS: 130250-55-4
• 化学式: C₇H₁₂N₂O₂
• 分子量: 156.184
• InChiKey: NADNERWNWVUWEZ-UHFFFAOYSA-N

物化性质

• 熔点：
  131-132 °C(Solv: acetonitrile (75-05-8))
• 沸点：
  424.1±34.0 °C(Predicted)
• 密度：
  1.274±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  63.4
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  3-哌啶甲酸乙酯 、 formamide 在 sodium methylate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.75h， 以84%的产率得到1-甲酰基-3-哌啶甲酰胺
  参考文献：
  名称：

  Jagdmann, G. Erik; Munson, H. Randall; Gero, Thomas W., Synthetic Communications, 1990, vol. 20, # 8, p. 1203 - 1208

  摘要：

  DOI：

文献信息

• CHEMICAL COMPOUNDS-821
  申请人：Finlay Maurice Raymond

  公开号：US20090048269A1

  公开（公告）日：2009-02-19

  The invention relates to chemical compounds of the formula (I), or pharmaceutically acceptable salts thereof, which possess ALK5 (TGFβR1) inhibitory activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of an anti-cancer effect in a warm-blooded animal such as man.

  该发明涉及化学式(I)的化合物，或其药学上可接受的盐，具有ALK5（TGFβR1）抑制活性，因此在抗癌活性方面有用，从而在治疗人体或动物体的方法中有用。该发明还涉及制造上述化学化合物的方法，含有它们的药物组合物，以及它们在制造用于在温血动物（如人）中产生抗癌效果的药物中的使用。
• [EN] PYRROLOPYRIMIDINECARBOXAMIDES<br/>[FR] PYRROLOPYRIMIDINE CARBOXAMIDES
  申请人：NYCOMED GMBH

  公开号：WO2009106531A1

  公开（公告）日：2009-09-03

  The compounds of Formula (I) wherein R1, R21, R22, R23, R24, Y and R3 have the meanings as given in the description, the salts thereof, the N-oxides of the compounds and the salts thereof and the stereoisomers of the compounds, the salts, the N-oxides of the compounds and the N-oxides of the salts thereof are effective inhibitors of the type 5 phosphodiesterase.

  Formula（I）中的化合物，其中R1、R21、R22、R23、R24、Y和R3的含义如描述中所述，其盐，化合物的N-氧化物及其盐，化合物的立体异构体，盐，化合物的N-氧化物及其盐的N-氧化物是有效的第5型磷酸二酯酶抑制剂。
• [EN] SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES<br/>[FR] INHIBITEURS DE METALLOPROTEASES MATRICES A BASE D'HYDROXAMATES CYCLIQUES SUBSTITUES
  申请人：INCYTE CORP

  公开号：WO2005037826A1

  公开（公告）日：2005-04-28

  The present invention provides compounds of the formula I: its enantiomers, diastereomers, racemic mixtures thereof, prodrugs, crystalline forms, non-crystalline forms, amorphous forms thereof, solvates thereof, metabolites thereof, and pharmaceutically acceptable salts, wherein the ring A substituent groups are fully defined in the following disclosure. The compounds of formula I are inhibitors of metalloproteases such as matrix metalloproteases and sheddases, and are useful in treating diseases such as rheumatoid arthritis, psoriasis, neoplastic diseases, allergies and all those diseases wherein inhibition of MMPs is desirable.

  本发明提供了公式I的化合物：其对映异构体，二对映异构体，混合物，前药，结晶形式，非晶形式，无定形形式，溶剂化物，代谢物和药学上可接受的盐，其中环A取代基在以下披露中被完全定义。公式I的化合物是金属蛋白酶抑制剂，如基质金属蛋白酶和剪切酶的抑制剂，并且在治疗风湿性关节炎，牛皮癣，肿瘤性疾病，过敏和所有需要MMPs抑制的疾病中有用。
• Carbazole derivatives and their use as neuropeptide y5 receptor ligands
  申请人：——

  公开号：US20040067999A1

  公开（公告）日：2004-04-08

  Compounds of formula (I): are described wherein R 1 -R 6 and m are as defined within. Processes for their preparation and their use as NPY 5 inhibitors is described.

  描述了化学式（I）的化合物，其中R1-R6和m的定义如所述。描述了它们的制备过程以及它们作为NPY 5抑制剂的用途。
• Novel bicyclic hydroxamates as inhibitors of histone deacetylase
  申请人：Leahy M Ellen

  公开号：US20060058553A1

  公开（公告）日：2006-03-16

  The present invention is directed to certain bicyclic hydroxamate derivatives that are inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed

  本发明涉及某些双环羟肟衍生物，它们是组蛋白去乙酰化酶的抑制剂，因此可以用于治疗与组蛋白去乙酰化酶活性相关的疾病。本发明还公开了制备这些化合物的制药组合物和过程。